BR112013028134A2 - “polipeptídeo de fusão, usos de um polipeptídeo de fusão, método para obter uma resposta imune, métodos para produzir um anticorpo, métodos para selecionar um anticorpo e anticorpo” - Google Patents

“polipeptídeo de fusão, usos de um polipeptídeo de fusão, método para obter uma resposta imune, métodos para produzir um anticorpo, métodos para selecionar um anticorpo e anticorpo”

Info

Publication number
BR112013028134A2
BR112013028134A2 BR112013028134A BR112013028134A BR112013028134A2 BR 112013028134 A2 BR112013028134 A2 BR 112013028134A2 BR 112013028134 A BR112013028134 A BR 112013028134A BR 112013028134 A BR112013028134 A BR 112013028134A BR 112013028134 A2 BR112013028134 A2 BR 112013028134A2
Authority
BR
Brazil
Prior art keywords
antibody
polypeptide
fusion polypeptide
methods
domain
Prior art date
Application number
BR112013028134A
Other languages
English (en)
Inventor
Christian Scholz
David Casagolda Vallribera
Hartmut Duefel
Herbert Andres
Michael Gerg
Michael Schraeml
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112013028134A2 publication Critical patent/BR112013028134A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)

Abstract

polipeptídeo de fusão, uso de um polipeptídeo de fusão, método para obter uma resposta imune em um animal experimental contra um polipeptídeo, para produzir uma anticorpo, para seleção de um anticorpo e anticorpo obtido por um método no presente pedido é relatado um polipeptídeo de fusão de acordo com a fórmula i: nh~ 2~s~ 2~x~ 1~-cooh (fórmula i) em que, x~ 1~ compreende tanto uma sequência aleatória de aminoácidos como uma sequência de aminoácidos derivada de um primeiro polipeptídeo, s~ 2~ e s~ 1~ são sequências de aminoácidos sem sobreposição, derivadas de um segundo polipeptídeo, e - denota uma ligação peptídica, em que o segundo polipeptídeo é um polipeptídeo com atividade de peptidil-propil cis-trans isomerase (atividade de pplase) ou é derivado da família do domínio de dobramento de fkbp, em que x~ 1~ é inserido no lugar do domínio flap na inserção (insert-in-flap-domain) do segundo polipeptídeo (domínio if).
BR112013028134A 2011-05-05 2012-05-04 “polipeptídeo de fusão, usos de um polipeptídeo de fusão, método para obter uma resposta imune, métodos para produzir um anticorpo, métodos para selecionar um anticorpo e anticorpo” BR112013028134A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11164957 2011-05-05
EP12155742 2012-02-16
PCT/EP2012/058207 WO2012150320A1 (en) 2011-05-05 2012-05-04 Amino acid sequence presenting fusion polypeptide and its use

Publications (1)

Publication Number Publication Date
BR112013028134A2 true BR112013028134A2 (pt) 2016-11-29

Family

ID=46022284

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028134A BR112013028134A2 (pt) 2011-05-05 2012-05-04 “polipeptídeo de fusão, usos de um polipeptídeo de fusão, método para obter uma resposta imune, métodos para produzir um anticorpo, métodos para selecionar um anticorpo e anticorpo”

Country Status (17)

Country Link
US (5) US9266962B2 (pt)
EP (2) EP2705053B1 (pt)
JP (3) JP6165713B2 (pt)
KR (1) KR101632479B1 (pt)
CN (2) CN103649119B (pt)
AR (1) AR086250A1 (pt)
AU (1) AU2012251584B2 (pt)
BR (1) BR112013028134A2 (pt)
CA (2) CA2831162C (pt)
ES (1) ES2637667T3 (pt)
IL (1) IL228983A0 (pt)
MX (1) MX340329B (pt)
MY (1) MY166542A (pt)
RU (1) RU2630660C2 (pt)
SG (1) SG194707A1 (pt)
WO (2) WO2012150321A1 (pt)
ZA (1) ZA201308251B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086250A1 (es) 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
ES2603589T3 (es) * 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
US9429584B2 (en) * 2013-02-28 2016-08-30 National Cancer Center Antibody against insoluble fibrin
WO2014138733A2 (en) * 2013-03-08 2014-09-12 Dessain Scott K Compositions and methods for making human antibodies
WO2015044083A1 (en) * 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Thermus thermophilus slyd fkbp domain specific antibodies
CA2945066A1 (en) * 2014-05-14 2015-11-19 F. Hoffmann-La Roche Ag Her1 antigen binding proteins binding to the beta-hairpin of her1
EP3143049B1 (en) 2014-05-14 2019-08-21 F. Hoffmann-La Roche AG Her3/her2 bispecific antibodies binding to the beta-hairpin of her3 and domain ii of her2
MX2017006866A (es) 2014-12-01 2017-11-15 Pfenex Inc Pares de unión para producción de péptidos.
CN107406515B (zh) * 2014-12-18 2022-11-04 生物梅里埃公司 合成的双表位化合物
JP6757319B2 (ja) 2014-12-19 2020-09-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 微生物トランスグルタミナーゼ、その基質、およびその使用方法
KR101873201B1 (ko) * 2015-06-11 2018-07-02 주식회사 제넥신 변형된 인터루킨-7 단백질 및 이의 용도
CN106554420A (zh) * 2015-09-30 2017-04-05 上海众合医药科技股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
WO2017095191A1 (ko) 2015-12-04 2017-06-08 주식회사 제넥신 면역글로불린 fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물
WO2017095140A1 (ko) 2015-12-04 2017-06-08 주식회사 제넥신 면역글로불린 fc가 융합된 인터루킨-7 융합 단백질을 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 약학적 조성물
KR20180087431A (ko) * 2015-12-15 2018-08-01 에프. 호프만-라 로슈 아게 트랜스글루타미나제 인식 부위를 갖는 fkbp 도메인
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
US11327078B2 (en) * 2018-02-27 2022-05-10 Eisai R&D Management Co., Ltd. Monoclonal antibody against APOA4, immunological measurement method, and kit for measurement
CN114430747A (zh) * 2019-09-26 2022-05-03 豪夫迈·罗氏有限公司 抗csf-1r抗体
WO2022263644A1 (en) 2021-06-17 2022-12-22 Roche Diagnostics Gmbh Thermostable affinity polypeptides
EP4380955A1 (en) * 2021-08-06 2024-06-12 Roche Diagnostics GmbH Chimeric igg-fc-binding ligand polypeptide and uses thereof for igg affinity purification
EP4388014A1 (en) 2021-08-19 2024-06-26 F. Hoffmann-La Roche AG Multivalent anti-variant fc-region antibodies and methods of use
CN116284220B (zh) * 2023-02-24 2024-08-20 浙江兴业集团有限公司 一种胆固醇酯酶抑制多肽组合及其制备方法、应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1232188A (en) 1987-05-29 1988-12-01 Mallinckrodt, Inc. Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5614547A (en) * 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
AU2002217505B2 (en) 2000-12-26 2006-03-02 Sekisui Chemical Co., Ltd. Process for producing recombinant protein and fused protein
CA2449747C (en) * 2001-06-22 2010-04-13 F. Hoffmann-La Roche Ag Use of fkbp chaperones as expression tool
CA2490384A1 (en) 2002-06-25 2003-12-31 Sekisui Chemical Co., Ltd. Expression vector, host, fused protein, process for producing fused protein and process for producing protein
DE60222817T2 (de) * 2002-12-20 2008-07-03 Roche Diagnostics Gmbh Lösliche komplexe von zielproteinen und peptidyl-prolyl-isomerase-chaperonen sowie deren herstellung und verwendung
WO2004092221A1 (ja) 2003-04-18 2004-10-28 Sekisui Chemical Co. Ltd. 免疫原及び免疫用組成物、並びにそれらを使用する抗体の製造方法
US7732564B2 (en) * 2005-04-28 2010-06-08 London Health Sciences Centre Research Inc. Serum tumor marker in rodent prostate cancer models
EP2279726A3 (en) * 2005-05-26 2012-06-20 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
CA2562738C (en) * 2005-10-26 2011-07-12 F. Hoffmann-La Roche Ag Soluble rubella e1 envelope antigens
EP1780282B1 (en) 2005-10-26 2010-12-08 Roche Diagnostics GmbH Recombinant expression of Rubella E1 envelope protein variants as chaperone fusion-proteins, and their use in the detection of anti-Rubella antibodies
CA2636075C (en) 2006-01-03 2011-11-08 F. Hoffmann-La Roche Ag Chimaeric fusion protein with superior chaperone and folding activities
EP2010567A2 (en) * 2006-04-07 2009-01-07 The Government of the United States of America as Represented by The Department of Health and Human Services Antibody compositions and methods for treatment of neoplastic disease
WO2010052344A2 (en) * 2008-11-10 2010-05-14 Novartis Ag Antibodies to modified human igf-1/e peptides
AR086250A1 (es) * 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
JP6488854B2 (ja) * 2015-04-22 2019-03-27 住友電気工業株式会社 半導体積層体および受光素子

Also Published As

Publication number Publication date
MX2013012688A (es) 2013-12-02
NZ616871A (en) 2015-12-24
US10301383B2 (en) 2019-05-28
MX340329B (es) 2016-07-06
AR086250A1 (es) 2013-11-27
CA2834456A1 (en) 2012-11-08
US20140120561A1 (en) 2014-05-01
CA2831162A1 (en) 2012-11-08
AU2012251584B2 (en) 2016-07-28
CA2831162C (en) 2019-05-28
JP2014515761A (ja) 2014-07-03
RU2630660C2 (ru) 2017-09-11
US20160138004A1 (en) 2016-05-19
CN103620031B (zh) 2016-11-23
JP2014520073A (ja) 2014-08-21
WO2012150320A1 (en) 2012-11-08
US20190367601A1 (en) 2019-12-05
JP5877893B2 (ja) 2016-03-08
AU2012251584A1 (en) 2013-11-07
KR20140004802A (ko) 2014-01-13
EP2705147A1 (en) 2014-03-12
US20160137728A1 (en) 2016-05-19
ES2637667T3 (es) 2017-10-16
IL228983A0 (en) 2013-12-31
EP2705147B1 (en) 2019-08-07
CN103649119B (zh) 2016-06-08
CN103620031A (zh) 2014-03-05
US9266962B2 (en) 2016-02-23
SG194707A1 (en) 2013-12-30
US9938340B2 (en) 2018-04-10
EP2705053A1 (en) 2014-03-12
MY166542A (en) 2018-07-16
US10647765B2 (en) 2020-05-12
WO2012150321A1 (en) 2012-11-08
JP2017048209A (ja) 2017-03-09
CN103649119A (zh) 2014-03-19
US9273144B2 (en) 2016-03-01
RU2013152691A (ru) 2015-06-10
ZA201308251B (en) 2014-08-27
JP6165713B2 (ja) 2017-07-19
US20140178393A1 (en) 2014-06-26
EP2705053B1 (en) 2017-06-14
KR101632479B1 (ko) 2016-06-21

Similar Documents

Publication Publication Date Title
BR112013028134A2 (pt) “polipeptídeo de fusão, usos de um polipeptídeo de fusão, método para obter uma resposta imune, métodos para produzir um anticorpo, métodos para selecionar um anticorpo e anticorpo”
MX2021015971A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
PH12017501114A1 (en) Anti-c5 antibodies and methods of use
WO2012142591A3 (en) Compositions, methods and uses for multiplex protein sequence activity relationship mapping
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
CO6811816A2 (es) Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminiácidos no naturales
WO2015089492A3 (en) Dna antibody constructs and method of using same
MX2023001360A (es) Anticuerpos anti-c5 y metodos de uso.
MX2013013111A (es) Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma.
IN2014DN05695A (pt)
MX2014011459A (es) Proteinas nutritivas cargadas y metodos.
IN2014DN07399A (pt)
WO2012047679A3 (en) Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2010086743A3 (en) Codon-optimised hepatitis b virus core antigen
EP2534168A4 (en) CHEMICAL PREPARATION OF UBIQUITIN THIOESTERS AND MODIFICATIONS THEREOF
MX354156B (es) Dipeptido que comprende un aminoacido no proteogenico.
EA201391669A1 (ru) Белок f - новый адгезин haemophilus influenzae, способный связывать ламинин и витронектин
WO2011151470A3 (en) Methods and helper viruses for the generation of rna virus
IN2014CN00436A (pt)
Cieplak Aqueous amino acids and proteins near solid surfaces: ZnO, ZnS, Au, and mica
AR102421A1 (es) Anticuerpos de un solo dominio dirigidos contra antígenos intracelulares
TH127404A (th) การใช้โปรตีนที่เป็นโฮโมโลกัสกับโปรตีน MeaB เพื่อเพิ่มแอคทิวิตี้ทางเอนไซม์ของ 3-ไฮดรอกซีคาร์บอกซิลิกแอซิด-CoA มิวเทส
NZ588664A (en) Prion epitopes and methods of use thereof
WO2012092629A3 (en) Methods, cells, and systems for incorporating non-canonical amino acids into proteins

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements